GlassScriptPhysician profile
Adam M Gude
NPI 1225482524
$3,823.43
in general payments reported to CMS, 2019-2025
28 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $448 · 2023: $630 · 2024: $1,001 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,240 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,240.27 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $893.07 | 2022-2025 | |
| Novo Nordisk INC | $639.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $330.99 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $248.09 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $238.26 | 2023-2025 | Verquvo, Steglatro |
| Corcept Therapeutics | $173.74 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $163.86 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.50 | 2025 | Caplyta |
| Amgen INC. | $122.48 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $114.28 | 2022-2024 | Freestyle Libre 3 |
| Insulet Corporation | $113.36 | 2022-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $110.19 | 2021-2023 | |
| Exact Sciences Corporation | $91.04 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $64.49 | 2022-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $51.43 | 2021-2023 | Gvoke Hypopen |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $37.88 | 2025 | Auvelity |
| Indivior INC. | $36.21 | 2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.79 | 2022-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $32.92 | 2022-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $26.61 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $25.36 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $20.70 | 2022 | |
| Lundbeck LLC | $20.12 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $20.06 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $16.50 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.06 | 2022 | |
| Genentech USA, INC. | $14.39 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Gude listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.